Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC009299 | Panoply™ Human MCAM Knockdown Stable Cell Line | Inquiry |
| CSC-SC009299 | Panoply™ Human MCAM Over-expressing Stable Cell Line | Inquiry |
| CSC-RT1078 | Human MCAM Knockout Cell Line-HeLa | Inquiry |
| CLOE-1716 | Human MCAM(His) HEK293 Cell Lysate | Inquiry |
| CLOE-1717 | Human MCAM HEK293 Cell Lysate | Inquiry |
| CLOE-2457 | Mouse Mcam HEK293 Cell Lysate | Inquiry |
| CLKO-0568 | MCAM KO Cell Lysate-HeLa | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD09740Z | Human MCAM adenoviral particles | Inquiry |
| LV17926L | human MCAM (NM_006500) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH180515 | shRNA set against Mouse Mcam(NM_023061.2) | Inquiry |
| SHH339087 | shRNA set against Human MCAM (NM_006500.2) | Inquiry |
| SHW000181 | shRNA set against Chicken MCAM (NM_001004768) | Inquiry |
| SHH180479 | shRNA set against Rat Mcam(NM_023983.3) | Inquiry |
| SHH180497 | shRNA set against Human MCAM(NM_006500.2) | Inquiry |
| SHH180533 | shRNA set against Rat Mcam(NM_001034009.1) | Inquiry |
| SHH339091 | shRNA set against Mouse MCAM (NM_023061.2) | Inquiry |
| SHH339095 | shRNA set against Rat MCAM (NM_023983.3) | Inquiry |
| SHW007909 | shRNA set against Danio rerio MCAMB (NM_001012367) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB161656 | Chicken MCAM ORF Clone (NM_001004768) | Inquiry |
| MiUTR1M-06991 | MCAM miRNA 3'UTR clone | Inquiry |
| MiUTR1H-06152 | MCAM miRNA 3'UTR clone | Inquiry |
| CDFR012238 | Rat Mcam cDNA Clone(NM_023983.3) | Inquiry |
| CDFR004329 | Rat Mcam cDNA Clone(NM_001034009.1) | Inquiry |
| CDFH011179 | Human MCAM cDNA Clone(NM_006500.2) | Inquiry |
| CDCS412773 | Human MCAM ORF Clone (BC056418) | Inquiry |
| MiUTR1R-03724 | MCAM miRNA 3'UTR clone | Inquiry |
| MiUTR1R-03725 | MCAM miRNA 3'UTR clone | Inquiry |
| CDCL185291 | Mouse MCAM ORF clone(NM_023061.2) | Inquiry |
| CDCL183186 | Human CD146 ORF clone(NM_006500.2) | Inquiry |
| CDCB196108 | Rabbit LOC103350909 ORF clone (XM_008268169.1) | Inquiry |
| CDCB191987 | Rabbit MCAM ORF clone (XM_008250510.1) | Inquiry |
| CDCB191222 | Rabbit C18H10orf35 ORF clone (XM_008270018.1) | Inquiry |
| CDCB169384 | Danio rerio MCAMB ORF Clone (NM_001012367) | Inquiry |
| CDCR371357 | Rat Mcam ORF Clone(NM_001034009.1) | Inquiry |
| CDCR379315 | Rat Mcam ORF Clone(NM_023983.3) | Inquiry |
The MCAM (Melanoma Cell Adhesion Molecule, also known as CD146) gene is located on chromosome 11q23.3 and encodes a single-pass transmembrane adhesion protein belonging to the immunoglobulin superfamily. Its protein structure consists of five extracellular Ig-like domains, a transmembrane segment, and a short cytoplasmic tail. MCAM mediates signal transduction by binding to ligands such as Wnt5a and Laminin-411, which activate non-receptor tyrosine kinases like FYNK and focal adhesion kinase PTK2/FAK1, triggering calcium signaling and downstream pathways.
CD146 is expressed in various cell types:
In terms of transcriptional regulation, CD146 promoter activity is significantly upregulated by hypoxia-inducible factor HIF-1α and the inflammatory cytokine TNF-α, while epigenetic modifications, such as histone H3K27 deacetylation, suppress its expression.
Biological Functions and Disease Mechanisms
CD146's primary role is to integrate environmental signals and reshape cellular behavior and tissue homeostasis:
A "molecular engine" of tumor metastasis: In osteosarcoma, CD146 drives malignancy through dual mechanisms:
A hub for immune microenvironment regulation: A study by the Key Laboratory of Tumor Immunity and Prevention in Yunnan, published in Nature Communications, revealed that MCAM deletion in mammary epithelial cells activates macrophages through the Wnt5a/Ryk axis, forming a positive feedback loop:
An amplifier of chronic inflammation: In COPD patients, CD146 is persistently overexpressed as a marker of endothelial injury. Flow cytometry indicates that during acute exacerbations, peripheral blood CD146 levels are 1.8 times higher than in stable phases. This is linked to NF-κB activation induced by TNF-α. High CD146 expression promotes neutrophil adhesion to pulmonary microvascular endothelium, exacerbating airway obstruction.
Figure 1. Schematic representation of CD146 cellular localization and regulation. (Joshkon A, et al., 2020)
CD146 holds dual clinical value as both a diagnostic marker and therapeutic target:
Prognostic models and precision therapy: A four-gene risk model based on osteosarcoma microarray data (CD146, ENPEP, LRRC1, CPE) accurately predicts metastasis and survival. CD146 carries the highest weight (HR = 1.323); patients with high CD146 expression have a 3-year survival rate of only 41%, compared to 82% in the low-expression group. The model also predicts drug sensitivity: CD146-high tumors are resistant to cytarabine (3.2-fold increase in IC50) but more sensitive to anthracyclines.
A novel target for immunotherapy: The anti-CD146 monoclonal antibody ABX-MA1 shows triple efficacy in breast cancer models:
Intervention in inflammatory diseases: The CD146-neutralizing antibody TF-016 reduces acute exacerbation frequency in COPD. Phase II clinical trials showed a 43% reduction in exacerbation events within 6 months and a 12.5% improvement in FEV1% predicted. The mechanism involves blocking neutrophil-endothelial adhesion.
Challenges and innovative directions: One challenge in targeting CD146 is tissue specificity. New peptide-antibody conjugates, such as CD146-PDPN bispecific antibodies, enable selective targeting of tumor vasculature and reduce side effects like skin hyperpigmentation. Additionally, patient stratification based on CD146 promoter methylation status (low methylation correlates with high expression) is advancing the development of personalized therapies.
References: